Journey Medical Corp

Journey Medical Corp. faces steep challenges: a negative P/E, fluctuating stock price, and a $220 M cap, yet its niche dermatology drugs could turn investor confidence and unlock growth.

Journey Medical Corp’s Q1 2025 earnings report showed a mixed bag of results, with the company surpassing revenue expectations but reporting a quarterly loss, sparking interest and speculation among investors and analysts.